Fieldview Capital Management’s Tango Therapeutics TNGX Stock Holding History

Fieldview Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Buy	+10,640	New	+$263K	0.09%	353

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fieldview Capital Management's TNGX Position: Q2 2026 in Review

Fieldview Capital Management opened a new position in Tango Therapeutics (TNGX) in Q2 2026: 10,640 shares worth $333K. The stake represents 0.09% of the portfolio and ranks #353 among its holdings.

247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

Fieldview Capital Management held 10,640 shares of Tango Therapeutics worth $333K as of Q2 2026.
Tango Therapeutics was a new Fieldview Capital Management position in Q2 2026.
Tango Therapeutics made up 0.09% of Fieldview Capital Management's portfolio in Q2 2026, its #353 holding.
247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.